Gastroesophageal Reflux Disease Therapeutics Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026 by FMI

Future Market Insights has announced the addition of the “Gastroesophageal Reflux Disease Therapeutics Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.

Gastroesophageal reflux disease involves the backflow of stomach’s content to mouth through esophagus which gives a burning sensation behind breast bone. Gastroesophageal reflux disease is a common digestive disorder which affects the food pipe and lower esophageal sphincter by deteriorating its elasticity. Gastroesophageal reflux disease occurs due to lifestyle changes and irregular eating habits & over consumption of fatty foods, coffee, alcoholic beverages, citrus fruits and pepper. In Gastroesophageal reflux disease there is excessive production of acid which damages the stomach lining and ultimately cause ulcers. Gastroesophageal reflux disease includes other symptoms such as regurgitation and dysphagia. However, abnormal reflux may cause uncharacteristic symptoms such as coughing, sore throat, otitis media, chest pain and enamel erosion or other dental manifestations.

Continuous acid reflux disease can cause inflammation of esophagus called as esophagitis. Gastroesophageal reflux disease is a result of unevenness between the normal resistance mechanisms of the esophagus and aggressive components such as acid and other digestive juices and enzymes in the stomach.Gastroesophageal reflux disease can also be caused by the overdoing of certain medicines, such as calcium channel blockers, nitrates and antihistamines.

Gastroesophageal Reflux Disease Therapeutics Market: Drivers & Restraints

Gastroesophageal reflux disease is a very common disease due to which the patient pool is very large.It affects all ages from infants to geriatric population. The prevalence of gastroesophageal reflux disease is increasing significantly across the globe. Increase in aging population is also one of the factor driving the growth of gastroesophageal reflux disease market. The increase number of patients pursuing gastroesophageal reflux disease treatment and long term anti-reflux conservation therapy are expected to endure the gastroesophageal reflux diseasemarket during the forecast period.Gastro esophageal reflux disease market is also affected by the rapidly changing eating habits and changes in lifestyle. Although, everything is in favor but there are some unavoidable restraints such as patent expiry and weak drug pipeline which will pull back the market. The competition is very strong as there are many products available in the market for symptomatic treatment.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1410

Gastroesophageal Reflux Disease Therapeutics Market: Segmentation

Gastroesophageal reflux disease market is classified on the basis of therapy, product and distribution channel.

Based on product type, the global gastroesophageal reflux disease therapeutics market is segmented into following:

Antacids

Proton pump inhibitors

H2 receptor blocker

Pro kinetic agents

Dopamine receptor antagonist

EndoCinch

Stretta

EsophyX

Transoral Incisionless fundoplication

Linx

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1410

Based on distribution channel, the global gastro esophageal reflux disease therapeutics market is segmented into the following:

Hospital pharmacy

Drug stores

General stores

Supermarkets

Gastroesophageal Reflux Disease Therapeutics Market: Overview

Gastroesophageal reflux disease therapeutics market is predicted to decline during the forecast period due to the patent expiry of major producers. Innovations in terms of treatment modalities and commercialization of cost effective medicines are expected to boost gastroesophageal reflux disease therapeutics market during the forecast period. Poor drug pipeline developments and minimal differentiation in term of drug therapy would hinder the growth of gastroesophageal reflux disease therapeutics market.

Gastroesophageal Reflux Disease Therapeutics Market: Region-wise Outlook

Based on geographic regions, gastroesophageal reflux disease therapeutics market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa. North America seized major share in the global market of gastroesophageal reflux disease therapeutics market due to increase in aging population and awareness of drug therapies followed by Western and Eastern Europe, Asia Pacific may have a negative impact on GERD in their daily lives due to which the acceptance rate of therapy is low and the prevalence in Asia pacific is low as well. The gastroesophageal reflux disease therapeutics market in japan will have a constant growth due to the balance between therapies and change in life style. Middle East and Africa holds promising future for rise in the global gastroesophageal reflux disease therapeutics market as expenditure on healthcare from foreign countries is increasing which is favouring the new drug development.

Browse Full Report@ http://www.futuremarketinsights.com/reports/gastroesophageal-reflux-disease-therapeutics-market

Gastroesophageal Reflux Disease Therapeutics Market: Key Players

There are many key performers in gastroesophageal reflux disease therapeutics market some of the names who are leading the market in gastroesophageal reflux disease therapeutics market worldwide are AstraZeneca, Addex Pharmacetuicals, Vecam, Medigus, Peer Medical, EndoGastric Solutions, Eisai Co., Ltd, Takeda Pharmaceutical Company Limited, RaQualia Pharma Inc, Reviva Pharmaceuticals Inc, Rottapharm Madaus, Torax Medical, Mederi Therapeutics, Aros, Pharma and others.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature.

616 Corporate Way, Suite 2-9018
Valley Cottage, NY

This release was published on openPR.